Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Creso Pharma (COPH.F) is considering speeding up its planned U.S. entry after a psychedelics bill passed through the Californian Senate
  • Senate Bill 519 essentially paves the way for the use and possession of psilocybin and other psychedelic compounds to be legalized
  • CPH has labelled the news encouraging, as it continues to progress the planned acquisition of Halucenex — a Canadian psilocybin business
  • Creso has appointed a Director of U.S. Business Development and a Strategic Advisor as it works to progress the Halucenex partnership
  • The company will also accelerate its agreement with U.S. scientific consulting firm, HetereoGeneity, to facilitate a faster market entry
  • Creso Pharma Ltd. (COPH.F) is up 26.77 per cent, trading at C$0.143 per share at 4pm ET

Creso Pharma (COPH.F) is considering speeding up its planned U.S. entry after a psychedelics bill passed through the Californian Senate.

Senate Bill 519 essentially paves the way for the use and possession of psilocybin and other psychedelics to be legalised in the state.

Creso has labelled the news encouraging as the company continues to progress its planned acquisition of psilocybin business Halucenex.

The Canadian company researches and develops psychedelics compounds, including psilocybin — the active ingredient in magic mushrooms.

To help facilitate entering the U.S. psychedelics market, Creso has appointed John Griese as Director of U.S. Business Development and Bruce Linton as Strategic Advisor.

Additionally, Creso has announced today it will accelerate its agreement with U.S. scientific consulting firm, HetereoGeneity, to facilitate a faster American entry

Creso Non-executive Chairman Adam Blumenthal said the company wants to be a first-mover in the U.S. psychedelics sector.

“This is a major development for Creso Pharma and Halucenex and provides a key strategy piece, which will underpin our expansion into the U.S. market,” he said.

“The board and management team are actively assessing a number of strategies to expedite a U.S. market entry and will leverage our existing partnerships and technical experience in the psychedelic space to unlock further value for shareholders”.

Creso Pharma Ltd. (COPH.F) is up 26.77 per cent, trading at C$0.143 per share at 4pm ET.

More From The Market Herald

" Optimi Health (CSE:OPTI) signs psilocybin supply agreement with Halucenex Life Sciences

Optimi Health (OPTI) has announced a supply agreement with Halucenex Life Sciences Inc., a wholly-owned subsidiary of Creso Pharma of Australia.

" Revive (CSE:RVV) gets FDA OK for Bucillamine trials to treat COVID-19

Revive Therapeutics (RVV), a cannabis and psychedelic healthcare company has received feedback from the U.S. FDA to help advance Bucillamine.

" Clearmind Medicine (CSE:MIND) and SciSparc report positive results for Psychedelic Combination Treatment

Clearmind Medicine (MND) has released favourable safety profile results from its joint pre-clinical trial with SciSparc Ltd. (NASDAQ: SPRC).

" Optimi Health (CSE:OPTI) acquires catalog of psychedelic and functional mushroom genetics

Optimi Health (OPTI) has acquired a catalog of psilocybin and functional mushroom strains.